Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Young Ho | - |
dc.contributor.author | Bae, Sang-Cheol | - |
dc.contributor.author | Song, Gwan Gyu | - |
dc.date.accessioned | 2021-08-02T18:54:15Z | - |
dc.date.available | 2021-08-02T18:54:15Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2013-10 | - |
dc.identifier.issn | 1756-1841 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/26628 | - |
dc.description.abstract | Objective The aim of this study was to assess the effects of anti-tumor necrosis factor (TNF) agents or disease-modifying antirheumatic drugs (DMARDs) on hepatitis B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg)-positive patients with rheumatic diseases. Methods Evidence of HBV reactivation after anti-TNF therapy or DMARDs in HBsAg-positive patients with rheumatic disease was summarized by performing a systematic review. Results A total of 122 HBsAg-positive rheumatic disease-positive patients undergoing treatment with an anti-TNF agent or with DMARDs were identified in nine studies. In eight of the studies, the anti-TNF agents used were etanercept in 56 cases, adalimumab in 25 cases and infliximab in 14 cases. Follow-up periods ranged from 6 to 52 months. Antiviral prophylaxis was administrated in 48 of the 122 patients (39.3%). HBV reactivation in HBsAg-positive patients taking an anti-TNF agent or DMARD was reported in 15 cases (15/122 = 12.3%). Ten of the 15 patients provided individual data on HBV reactivation: four patients had rheumatoid arthritis, four had ankylosing spondylitis and two had psoriatic arthritis; four received etanercept, and two received infliximab. In one of the four etanercept-treated cases in which the patient had elevated HBV-DNA levels, antiviral prophylaxis was also administered. Antiviral treatment was also administered in seven patients receiving other treatments: lamivudine in one, adefovir in one and entecavir in five. Clinical outcomes were satisfactory in all 10 cases of HBV reactivation. Conclusions Hepatitis B virus reactivation was found in 15 (12.3%) patients among the 122 HBsAg-positive patients with rheumatic diseases treated with anti-TNF agents or DMARDs. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY-BLACKWELL | - |
dc.title | Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Bae, Sang-Cheol | - |
dc.identifier.doi | 10.1111/1756-185X.12154 | - |
dc.identifier.scopusid | 2-s2.0-84886524794 | - |
dc.identifier.wosid | 000326156700006 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, v.16, no.5, pp.527 - 531 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES | - |
dc.citation.title | INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES | - |
dc.citation.volume | 16 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 527 | - |
dc.citation.endPage | 531 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.subject.keywordPlus | FACTOR-ALPHA ANTAGONISTS | - |
dc.subject.keywordPlus | HBV REACTIVATION | - |
dc.subject.keywordPlus | RETROSPECTIVE ANALYSIS | - |
dc.subject.keywordPlus | ARTHRITIS PATIENTS | - |
dc.subject.keywordPlus | INFECTION | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | PSORIASIS | - |
dc.subject.keywordPlus | CARRIERS | - |
dc.subject.keywordPlus | AGENTS | - |
dc.subject.keywordAuthor | anti-tumor necrosis factor therapy | - |
dc.subject.keywordAuthor | DMARD | - |
dc.subject.keywordAuthor | hepatitis B virus reactivation | - |
dc.subject.keywordAuthor | rheumatic diseases | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1111/1756-185X.12154 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.